AMoon leads £23m series-A for Mina Therapeutics

The Israel-based firm is currently investing from its second-generation fund, which closed on $660m in 2019. Following demand for new healthcare technology in 2020 due to the coronavirus crisis, the fund was reopened and expanded to hold another close on $750m in July.

The fund invests $10-25m in startups and reserves capital for subsequent investment rounds.

The proceeds from the financing will be used to advance Mina's pipeline of proprietary RNA therapeutics and support the continued clinical development of the company's lead candidate.

Gur Roshwalb, a managing director for AMoon, has joined the board of directors at Mina.

Company
Founded in 2008 and based in London, Mina performs research and experimental development for therapies to combat cancer.

People
AMoon – Gur Roshwalb (managing director).

Advisers
Company – MTS Securities (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• UK / Ireland
• Healthcare
• United Kingdom
• healthcare